By Prakhar Srivastava (Reuters) -Shares of weight-loss drug developer Metsera surged nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture Partners-backed biotech firm at $2.68 ...

These compounds take a different approach to weight loss than existing medications, which can cause nausea, vomiting and ...

now popular weight loss medications, on adverse mental health outcomes." Metsera is leaving no fundraising stone unturned as it races to grab a slice of the fast-growing market for obesity drugs.

If any more evidence were needed of a bounceback in venture financing for biotechs after a dip in 2023, the $400 million first round just announced by Mirador Therapeutics should suffice.